Cementoin–SLPI fusion protein binds to human monocytes and epithelial cells and shows higher biological activity than SLPI

[1]  H. E. Chuluyan,et al.  SLPI (secretory leukocyte peptidase inhibitor) , 2017 .

[2]  P. Maffía,et al.  Transglutaminase binding fusion protein linked to SLPI reduced corneal inflammation and neovascularization , 2015, BMC Ophthalmology.

[3]  H. You,et al.  Transglutaminase-2 induces N-cadherin expression in TGF-β1-induced epithelial mesenchymal transition via c-Jun-N-terminal kinase activation by protein phosphatase 2A down-regulation. , 2013, European journal of cancer.

[4]  O. Wiedow,et al.  Therapeutic potential of human elafin. , 2011, Biochemical Society transactions.

[5]  J. Sallenave,et al.  Serine leucocyte proteinase inhibitor‐treated monocyte inhibits human CD4+ lymphocyte proliferation , 2011, Immunology.

[6]  J. Huntington.  Serpin structure, function and dysfunction , 2011, Journal of thrombosis and haemostasis : JTH.

[7]  V. Labas,et al.  Secretory Leukocyte Protease Inhibitor (SLPI) Is, like Its Homologue Trappin-2 (Pre-Elafin), a Transglutaminase Substrate , 2011, PloS one.

[8]  C. Khosla,et al.  Characterization of transglutaminase type II role in dendritic cell differentiation and function , 2010, Journal of leukocyte biology.

[9]  V. García,et al.  Secretory leukocyte protease inhibitor: a secreted pattern recognition receptor for mycobacteria. , 2009, American journal of respiratory and critical care medicine.

[10]  M. Maki,et al.  Transglutaminase 2 activity promotes membrane resealing after mechanical damage in the lung cancer cell line A549 , 2008, Cell biology international.

[11]  J. Cowland,et al.  The secretory leukocyte protease inhibitor (SLPI) and the secondary granule protein lactoferrin are synthesized in myelocytes, colocalize in subcellular fractions of neutrophils, and are coreleased by activated neutrophils , 2008, Journal of leukocyte biology.

[12]  L. Tuosto,et al.  Transglutaminase Type II Is Involved in the Pathogenesis of Endotoxic Shock1 , 2008, The Journal of Immunology.

[13]  V. García,et al.  Neutrophil elastase converts human immature dendritic cells into transforming growth factor-beta1-secreting cells and reduces allostimulatory ability. , 2007, The American journal of pathology.

[14]  S. Tajima,et al.  Accumulation of elafin in actinic elastosis of sun-damaged skin: elafin binds to elastin and prevents elastolytic degradation. , 2007, The Journal of investigative dermatology.

[15]  R. Ientile,et al.  Tissue transglutaminase and the stress response , 2007, Amino Acids.

[16]  T. Dittmar,et al.  Alteration in the gene expression pattern of primary monocytes after adhesion to endothelial cells , 2007, Proceedings of the National Academy of Sciences.

[17]  N. McElvaney,et al.  Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding , 2005, The Journal of experimental medicine.

[18]  N. McElvaney,et al.  Secretory Leucoprotease Inhibitor Impairs Toll-Like Receptor 2- and 4-Mediated Responses in Monocytic Cells , 2004, Infection and Immunity.

[19]  R. Levine,et al.  Cathepsin B, L, and S Cleave and Inactivate Secretory Leucoprotease Inhibitor* , 2001, The Journal of Biological Chemistry.

[20]  S. Akimov,et al.  Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. , 2001, Blood.

[21]  M. Si-Tahar,et al.  Constitutive and regulated secretion of secretory leukocyte proteinase inhibitor by human intestinal epithelial cells. , 2000, Gastroenterology.

[22]  J. Schalkwijk,et al.  The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. , 1999, The Biochemical journal.

[23]  Bowness Jm,et al.  Increase in transglutaminase and its extracellular products in response to an inflammatory stimulus by lipopolysaccharide. , 1997 .

[24]  H. Lilja,et al.  Secretory leucocyte protease inhibitor in the male genital tract: PSA-induced proteolytic processing in human semen and tissue localization. , 1995, Journal of andrology.

[25]  Y. Suzuki,et al.  Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed "cementoin". , 1994, Journal of biochemistry.

[26]  R. F. Hoyt,et al.  Intravenous recombinant secretory leukoprotease inhibitor augments antineutrophil elastase defense. , 1992, Journal of applied physiology.

[27]  K. Ohlsson,et al.  The elimination of secretory leukocyte protease inhibitor (SLPI) after intravenous injection in dog and man. , 1990, Scandinavian journal of clinical and laboratory investigation.

[28]  K.,et al.  Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. , 1990, The Journal of biological chemistry.

[29]  R. Thompson,et al.  Pharmacokinetics and distribution of recombinant secretory leukocyte proteinase inhibitor in rats. , 1990, The American review of respiratory disease.

[30]  K. Ohlsson,et al.  Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Bieth,et al.  Influence of elastin on the inhibition of leucocyte elastase by alpha 1-proteinase inhibitor and bronchial inhibitor. Potent inhibition of elastin-bound elastase by bronchial inhibitor. , 1986, The Biochemical journal.

[32]  P. Moore,et al.  Enhanced transglutaminase activity associated with macrophage activation. Possible role in Fc-mediated phagocytosis. , 1982, Experimental cell research.

[33]  J. Sallenave,et al.  SLPI and elafin: one glove, many fingers. , 2006, Clinical science.

[34]  J. Bowness,et al.  Increase in transglutaminase and its extracellular products in response to an inflammatory stimulus by lipopolysaccharide , 2004, Molecular and Cellular Biochemistry.